Dupilumab is prescribed for:
- Moderate-to-severe atopic dermatitis (eczema)
- Moderate-to-severe asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis
- Dermatologic and respiratory conditions
Generic Name: Dupilumab
Brand Names: Dupixent
Dupilumab is a biologic that blocks IL-4 and IL-13 for moderate-to-severe atopic dermatitis, asthma, and nasal polyps.
Dupilumab is prescribed for:
Common side effects:
Serious side effects:
Dupilumab is a monoclonal antibody that blocks IL-4 and IL-13 signaling, key drivers of type 2 inflammation.
Approved for several conditions driven by type 2 inflammation:
Conjunctivitis and keratitis are more common with dupilumab, especially in atopic dermatitis patients.
For details, see MedlinePlus.
This medication is commonly used to treat or manage the following conditions:
Asthma, a chronic lung disease, causes airway inflammation and narrowing, resulting in wheezing, coughing, and shortness of breath, triggered by allergens, irritants, infections, or stress.
Dermatitis is skin inflammation with varied causes, including irritants, allergens, genetics (eczema), yeast overgrowth, or poor circulation, resulting in itchy rashes and dryness.
Sinusitis involves sinus inflammation and blockage due to infections, allergies, or structural issues, causing facial pain, pressure, and congestion, often following colds or triggered by allergens.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Have questions about Dupilumab? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.